JAK2 Targeted Mutation Analysis (V617F Mutation)
Myeloproliferative disorders include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF). These conditions are often associated with acquired mutation(s) in the JAK2 gene. The JAK2 V617F mutation is the most common molecular abnormality observed in BCR-ABL negative chronic myeloproliferative disorders. It is found in 65-97% of PV, 23-75% of ET, and 35-57% of IMF. It can occasionally be seen in acute and chronic leukemias. This mutation is not normally observed in healthy individuals. The V617F mutation causes a change of valine to phenylalanine at positon 617, and appears to render hematopoietic cells more sensitive to growth factors. Identification of this mutation in a symptomatic patient may have diagnostic and therapeutic significance.
Reasons for Referral
Individual with suspected myeloproliferative disorder for diagnostic and therapeutic purposes
PCR and gel electrophoresis
Turn Around Time
5 days or fewer
Specimen Requirements and Shipping/Handling
Blood: A single tube with 1-5 mL whole blood in EDTA (lavender top).
Store blood at 4°C until shipment. Ship at ambient temperature in an insulated container via overnight delivery within 96 hours of collection.
Send Specimen(s) to:
211. S Main Street
Orange, CA 92868
This assay has a lower limit of detection of 1-5% mutant cells in a background of normal cells, is qualitative, and is not designed to distinguish between heterozygous and homozygous mutations. Results of this test are recommended to be interpreted in the context of relevant pathology and clinical data.
CPT’s: 81270, G0452